Plasma samples from COVID-19 patients contained mainly high titers of SARS-CoV-2 RBD, S1, and S2-specific binding antibodies. Plasma from COVID-19 patients was not effective in inhibiting SARS-CoV infection in PsV neutralization assay. However, it showed some cross-binding activity with the SARS-CoV antibodies, possibly explained by the conserved epitopes between SARS-CoV-2 and SARS-CoV spike proteins. This data suggest that the immunogenicity between SARS-CoV-2 and SARS-CoV is different.